Neoplasms

Heart and Blood Diseases

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Multiple Myeloma

Neoplasms, Plasma Cell

Neoplasms by Histologic Type

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Paraproteinemias

Blood Protein Disorders

Hematologic Diseases

Hemorrhagic Disorders

Lymphoproliferative Disorders

Immunoproliferative Disorders

genetic sequencing

Leif Bergsagel, M.D.

This protocol is now being used as screening for the MyDRUG study

Here we propose an "integrative sequencing approach" utilizing a 1500 gene exome comparative analysis between multiple myeloma or related plasma cell malignancies and normal cells coupled to capture transcriptome sequencing to provide a nearly comprehensive landscape of the genetic alterations for the purpose of identifying informative and/or actionable mutations in patients with multiple myeloma and plasma cell malignancies. The approach will enable the detection of point mutations, insertions/deletions, gene fusions and rearrangements, amplifications/deletions, and outlier expressed genes among other classes of alterations.

bone marrow and peripheral blood samples will be obtained

MMRF Molecular Profiling Protocol

Clinical-grade Molecular Profiling of Patients With Multiple Myeloma and Related Plasma Cell Malignancies

Multiple Myeloma Research Foundation

Molecular profiled group receiving treatment based on genetics

Patients and their treating physician will obtain the patient's genetic risk assessment

Molecular profile

Brian Leyland-Jones

The primary aim of this study is to identify drivers of cancer by performing comprehensive genetic, proteomic, and metabolomic characterization of patient samples as a basis for understanding the underlying cause of disease.

This study involves looking at the DNA, RNA, proteins, and metabolites in blood and tissue samples collected from subjects and linking them to their health information. By doing so, researchers hope to discover the underlying molecular causes of human diseases with the hope that this information can be used for the development of diagnostic tests and more effective treatments.

Participants will have up to 3 blood tubes (about 30 ml) drawn under the condition that protocol criteria for blood sampling is met. Blood samples may be collected each time a participant undergoes a provider-ordered blood draw. Urine samples may also be collected approximately every 4-6 weeks.

Participants may be asked to provide approximately 60-120 ml of first-morning-void urine. Tissue from a standard care surgical procedure or biopsy may be obtained. Additional core biopsies (for research) or excess surgical waste will be collected during each biopsy procedure when appropriate and will be processed and stored.

Identifying Molecular Drivers of Cancer

To determine genetic changes associated with the development and growth of human disease. This should lead to better ways to detect, prevent, and treat a wide variety of human health conditions, including cancer.

Avera McKennan Hospital & University Health Center

Digestive System Diseases

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Dr. Naureen Starling, BSc, MBBS, MRCP

Annie Woodburne, BSc, MSc

Annie Woodburne, MSc, BSc

Dr. Sing Yu Moorcraft, MB BCh, MRCP

This study will assess the feasibility of sequencing locally advanced/metastatic gastrointestinal cancers in real-time to enable future treatment stratification by molecular characteristics. Targeted next generation sequencing of a panel of genes will be performed on tumour specimens and results will be discussed at a Sequencing Tumour Board to establish if a patient is potentially suitable for a targeted therapy.

Both fresh frozen tissue and formalin-fixed paraffin-embedded (FFPE) tumour samples will be obtained.

Biopsies may be taken at entry to the study and/or at the time of radiological response assessment. Each patient can have a maximum of 3 research biopsies in this study.

Up to 35 ml of blood will be collected at study entry to provide normal germline DNA and for possible additional biomarker analysis. If the patient has consented to optional blood sample collection, then additional blood samples will also be collected at the time of radiological response assessment to study molecular changes that occur during treatment.

Feasibility of a Molecular Characterisation Approach to Treatment

FOrMAT - Feasibility of a Molecular Characterisation Approach to Treatment

To examine tumour heterogeneity in patients with paired specimens

To assess the potential impact of genetic sequencing results on patients' treatment

To assess whether genetic sequencing results can be obtained within a clinically meaningful timeframe

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
MMRF Molecular Profiling Protocol	NCT02884102	Multiple Myelom... Plasma Malignan...	genetic sequenc...	18 Years -	Multiple Myeloma Research Foundation
Identifying Molecular Drivers of Cancer	NCT02470715	Cancer Tumor Advanced Cancer	Molecular profi...	18 Years -	Avera McKennan Hospital & University Health Center
Feasibility of a Molecular Characterisation Approach to Treatment	NCT02112357	Advanced Gastro...		18 Years -	Royal Marsden NHS Foundation Trust
Feasibility of a Molecular Characterisation Approach to Treatment	NCT02112357	Advanced Gastro...		18 Years -	Royal Marsden NHS Foundation Trust
Identifying Molecular Drivers of Cancer	NCT02470715	Cancer Tumor Advanced Cancer	Molecular profi...	18 Years -	Avera McKennan Hospital & University Health Center

Spots Global Cancer Trial Database for genetic sequencing